Slide 1: Conference Call Preliminary Full-Year 2019 Results
SEE sartorius | <3 sartorius Conference Call Preliminary Full-Year 2019 Results Joachim Kreuzburg (CEO), Rainer Lehmann (CFO) January 28, 2020
Slide 2: Disclaimer
- sartorius - sartorius Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward- looking statements are real
Slide 3: Sartorius Group FY 2019 Results | FY 2020 Guidance
= sartorius = sartorius Sartorius Group FY 20 2019 Results | FY 2020 Guidance | \ La. hee Sartorius Stedim Biotech h Group FY 2019 Results 5 FY 2020 Guidance 5 choos Questions & Answe
Slide 4: FY 2019 Highlights
FY 2019 Highlights WwW WY NY NN Double-digit growth in sales revenue, order intake and profit Bioprocess Solutions Division with continued high growth momentum Robust development of Lab Products & Services Division Acquisition of cell culture media specialist Biological Industries Acquisition of sel
Slide 5: Dynamic top-line growth; further margin increase
- sartorius Dynamic top-line growth; further margin increase Sartorius Group in millions of € unless otherwise specified FY 2018 FY 2019 A in % A in % ec 9 Sales revenue 1,566.0 1,827.0 16.7 14.8 Order intake 1,662.5 1,939.5 16.7 14.8 Underlying EBITDA”) 405.0 495.8 22.4 Underlying EBITDA?) margin i
Slide 6: Sales by Region
Americas Asia|Pacific Sales by Region +17.4 % +11.2 % +17.4 % • Americas: BPS with significant growth against high comps; LPS with strong performance • EMEA: Considerable growth of BPS; LPS affected by softer economy, especially in Q2 • Asia|Pacific: BPS with highest momentum, LPS grows slightly aga
Slide 7: Bioprocess Solutions: Order Intake and Sales Revenue
Order Intake Sales Revenue € in millions € in millions € in millions +18.0% cc +18.1% cc +24.5% +19.9% +20.0% • Order intake driven by dynamic project business • Effects of modified setup of the cell culture media business showed an increasing effect over the course of the year • Underlying EBITDA m
Slide 8: Lab Products & Services: Order Intake and Sales Revenue
Order Intake Sales Revenue € in millions € in millions € in millions +5.7% cc +5.9% cc +14.0% +7.3% +7.5% • Economic environment dampened growth, especially EMEA and Asia|Pacific were affected • Bioanalytics with positive momentum • Underlying EBITDA margin positively impacted by IFRS 16
Slide 9: Cash flow improves significantly
Cash flow improves significantly Sartorius Group € in millions unless otherwise specified FY 2018 FY 2019 Ain % Underlying EBITDA 405.0 495.8 22.4 Extraordinary items -1.7 -28.4 n.m. Financial result -27.9 -32.5 -16.4 Underlying net profit'?) 175.6 209.3 19.2 Reported net profit?) 141.3 156.7 10.9 O
Slide 10: Equity ratio influenced by application of IFRS 16
• Equity ratio influenced by application of IFRS 16
Slide 11: Outlook for 2020
Outlook for 2020 - sartorius FY 2019 FY 2020 Guidance”) Sales Revenue Underlying EBITDA Sales Revenue Underlying EBITDA Growth) Margin Growth Margin Sartorius Group 14.8% 27.1% ~ 10% - 13% ~ 27.5% Bioprocess Solutions 18.1% 29.6% ~ 11% - 14% ~ 30.0% Lab Products & Services 5.9% 19.6% ~ 7% - 10% ~ 20
Slide 12: Acquisition of Biological Industries
sartorius - sartorius Acquisition of Biological Industries Developer and manufacturer of cell culture media Specializes in media for advanced therapies (cell and gene therapies) 130 employees; headquartered in Beit Haemek, near Haifa (Israel) 2019 revenue €20m to €25m with healthy growth profile; sl
Slide 13: Announced acquisition of select life science assets from Danaher
sartorius - sartorius Announced acquisition of select life science assets from Danaher » Announced in 04 2019, transaction expected to close around the end of Q1 2020 with no impact on 2019 figures » Transaction is subject to Danaher's successful acquisition of the GE Biopharma business » Deal inclu
Slide 14: Sartorius Stedim Biotech Group FY 2019 Results | FY 2020 Guidance
- sartorius sv — E Sartorius Stedim Biotech Group Lr i FY 2019 Results | FY 2020 G auestons & Answer : Y= _—_ 14
Slide 15: Dynamic growth driven by high demand
Dynamic growth driven by high demand Sartorius Stedim Biotech Group in millions of € unless otherwise specified - sartorius across the entire portfolio FY 2018 FY 2019 A in % A in % cc 9 Sales revenue 1,212.2 1,440.6 +18.8 +17.0 Order intake 1,307.3 1,543.5 +18.1 +16.2 Underlying EBITDA” 342.4 421.5
Slide 16: Sales by Region
Americas Asia|Pacific Sales by Region +17.1% +13.0% +23.9% • Americas: Strong development relative to high comps • EMEA: Dynamic, above-market growth • Asia|Pacific: High momentum in sales and order intake, driven by project business
Slide 17: Significant increase in operating cash flow
Significant increase in operating cash flow - sartorius Sartorius Stedim Biotech Group € in millions unless otherwise specified FY 2018 FY 2019 A in % * Net operating cash flow mostly driven , by higher earnings and by factoring of Underlying EBITDA 342.4 421.5 +23.1 receivables in the amount of €27
Slide 18: Equity ratio influenced by application of IFRS 16
• Equity ratio influenced by application of IFRS 16
Slide 19: Outlook for 2020
- sartorius Outlook for 2020 FY 2020 Guidance FY 2019 FY 2020") Sales revenue growth 17.0%!) ~ 11% - 14% Underlying EBITDA margin 29.3 ~ 29.5 CAPEX ratio 9.4% ~ 8% * Growth guidance includes non-organic contribution by acquisition of Biological Industries of ~2pp ¢ Sartorius Stedim Biotech is set to
Slide 20: Questions & Answers
SEE sartorius | <3 sartorius Questions & Answers
Slide 21: SEE sartorius | <3 sartorius
SEE sartorius | <3 sartorius